Delineating the Mechanism of Alzheimer’s Disease Aβ Peptide Neurotoxicity (original) (raw)

• Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 297:353–356
  PubMed CAS Google Scholar
• Masters CL, Cappai R, Barnham KJ et al (2006) Molecular mechanisms for Alzheimer’s disease: implications for neuroimaging and therapeutics. J Neurochem 97:1700–1725
  PubMed CAS Google Scholar
• Kang J, Lemaire H, Unterbeck A et al (1987) The precursor of Alzheimer’s disease amyloid A4 protein resembles a cell-surface receptor. Nature 325:733–736
  PubMed CAS Google Scholar
• Haass C, Schlossmacher MG, Hung AY et al (1992) Amyloid β-peptide is produced by cultured cells during normal metabolism. Nature 359:322–325
  PubMed CAS Google Scholar
• Jarrett JT, Berger EP, Lansbury PT Jr (1993) The carboxy terminus of the β amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer’s disease. Biochemistry 32:4693–4697
  PubMed CAS Google Scholar
• Liao MQ, Tzeng YJ, Chang LY et al (2007) The correlation between neurotoxicity, aggregative ability and secondary structure studied by sequence truncated Abeta peptides. FEBS Lett 581:1161–1165
  PubMed CAS Google Scholar
• Yankner BA, Duffy LK, Kirschner DA (1990) Neurotrophic and neurotoxic effects of amyloid β protein: reversal by tachykinin neuropeptides. Science 250:279–282
  PubMed CAS Google Scholar
• Pike CJ, Burdick D, Walencewicz AJ et al (1993) Neurodegeneration induced by β-amyloid peptides in vitro: the role of peptide assembly state. J Neurosci 13:1676–1687
  PubMed CAS Google Scholar
• Pike CJ, Walencewicz AJ, Glabe CG et al (1991) In vitro aging of β-amyloid protein causes peptide aggregation and neurotoxicity. Brain Res 563:311–314
  PubMed CAS Google Scholar
• Pike CL, Walencewicz AJ, Glabe CG et al (1991) Aggregation-related toxicity of synthetic β-amyloid protein in hippocampal cultures. Eur J Pharmacol 207:367–368
  PubMed CAS Google Scholar
• Walsh DM, Klyubin I, Fadeeva JV et al (2002) Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416:535–539
  PubMed CAS Google Scholar
• Lambert MP, Barlow AK, Chromy BA et al (1998) Diffusible, nonfibrillar ligands derived from Ab1–42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 95:6448–6453
  PubMed CAS Google Scholar
• Smith DP, Ciccotosto GD, Tew DJ et al (2007) Concentration dependent Cu(2+) induced aggregation and dityrosine formation of the Alzheimer’s disease amyloid-beta peptide. Biochemistry 46:2881–2891
  PubMed CAS Google Scholar
• Barghorn S, Nimmrich V, Striebinger A et al (2005) Globular amyloid beta-peptide oligomer—a homogenous and stable neuropathological protein in Alzheimer’s disease. J Neurochem 95:834–847
  PubMed CAS Google Scholar
• Lesne S, Koh MT, Kotilinek L et al (2006) A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440:352–357
  PubMed CAS Google Scholar
• McLean CA, Cherny RA, Fraser FW et al (1999) Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer’s disease. Ann Neurol 46:860–866
  PubMed CAS Google Scholar
• Lue LF, Kuo YM, Roher AE et al (1999) Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer’s disease. Am J Pathol 155:853–862
  PubMed CAS Google Scholar
• Wang J, Dickson DW, Trojanowski JQ et al (1999) The levels of soluble versus insoluble brain Abeta distinguish Alzheimer’s disease from normal and pathologic aging. Exp Neurol 158:328–337
  PubMed CAS Google Scholar
• Naslund J, Haroutunian V, Mohs R et al (2000) Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 283:1571–1577
  PubMed CAS Google Scholar
• Yun SH, Gamkrelidze G, Stine WB et al (2006) Amyloid-beta1–42 reduces neuronal excitability in mouse dentate gyrus. Neurosci Lett 403:162–165
  PubMed CAS Google Scholar
• Klyubin I, Walsh DM, Cullen WK et al (2004) Soluble Arctic amyloid beta protein inhibits hippocampal long-term potentiation in vivo. Eur J Neurosci 19:2839–2846
  PubMed Google Scholar
• Klyubin I, Walsh DM, Lemere CA et al (2005) Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. Nat Med 11:556–561
  PubMed CAS Google Scholar
• Trommer BL, Shah C, Yun SH et al (2005) ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1–42. Neurobiol Dis 18:75–82
  PubMed CAS Google Scholar
• Wang HW, Pasternak JF, Kuo H et al (2002) Soluble oligomers of beta amyloid (1–42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res 924:133–140
  PubMed CAS Google Scholar
• Chen QS, Kagan BL, Hirakura Y et al (2000) Impairment of hippocampal long-term potentiation by Alzheimer amyloid beta-peptides. J Neurosci Res 60:65–72
  PubMed CAS Google Scholar
• Cleary JP, Walsh DM, Hofmeister JJ et al (2005) Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci 8:79–84
  PubMed CAS Google Scholar
• Small DH, Mok SS, Bornstein JC (2001) Alzheimer’s disease and Abeta toxicity: from top to bottom. Nat Rev Neurosci 2:595–598
  PubMed CAS Google Scholar
• Puzzo D, Palmeri A, Arancio O (2006) Involvement of the nitric oxide pathway in synaptic dysfunction following amyloid elevation in Alzheimer’s disease. Rev Neurosci 17:497–523
  PubMed CAS Google Scholar
• Wang Q, Walsh DM, Rowan MJ et al (2004) Block of long-term potentiation by naturally secreted and synthetic amyloid beta-peptide in hippocampal slices is mediated via activation of the kinases c-Jun N-terminal kinase, cyclin-dependent kinase 5, and p38 mitogen-activated protein kinase as well as metabotropic glutamate receptor type 5. J Neurosci 24:3370–3378
  PubMed CAS Google Scholar
• Minogue AM, Schmid AW, Fogarty MP et al (2003) Activation of the c-Jun N-terminal kinase signaling cascade mediates the effect of amyloid-beta on long term potentiation and cell death in hippocampus: a role for interleukin-1beta? J Biol Chem 278:27971–27980
  PubMed CAS Google Scholar
• Chong YH, Shin YJ, Lee EO et al (2006) ERK1/2 activation mediates Abeta oligomer-induced neurotoxicity via caspase-3 activation and tau cleavage in rat organotypic hippocampal slice cultures. J Biol Chem 281:20315–20325
  PubMed CAS Google Scholar
• Chin J, Palop JJ, Yu GQ et al (2004) Fyn kinase modulates synaptotoxicity, but not aberrant sprouting, in human amyloid precursor protein transgenic mice. J Neurosci 24:4692–4697
  PubMed CAS Google Scholar
• Braithwaite SP, Paul S, Nairn AC et al (2006) Synaptic plasticity: one STEP at a time. Trends Neurosci 29:452–458
  PubMed CAS Google Scholar
• Snyder EM, Nong Y, Almeida CG et al (2005) Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci 8:1051–1058
  PubMed CAS Google Scholar
• Rapoport M, Dawson HN, Binder LI et al (2002) Tau is essential to beta-amyloid-induced neurotoxicity. Proc Natl Acad Sci USA 99:6364–6369
  PubMed CAS Google Scholar
• Sengupta A, Novak M, Grundke-Iqbal I et al (2006) Regulation of phosphorylation of tau by cyclin-dependent kinase 5 and glycogen synthase kinase-3 at substrate level. FEBS Lett 580:5925–5933
  PubMed CAS Google Scholar
• Lewis J, Dickson DW, Lin WL et al (2001) Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293:1487–1491
  PubMed CAS Google Scholar
• Gotz J, Chen F, van Dorpe J et al (2001) Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science 293:1491–1495
  PubMed CAS Google Scholar
• Roberson ED, Scearce-Levie K, Palop JJ et al (2007) Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer’s disease mouse model. Science 316:750–754
  PubMed CAS Google Scholar
• Ambroggio EE, Kim DH, Separovic F et al (2005) Surface behavior and lipid interaction of Alzheimer {beta}-amyloid peptide 1–42:a membrane-disrupting peptide. Biophys J 88:2706–2713
  PubMed CAS Google Scholar
• Bhatia R, Lin H, Lal R (2000) Fresh and globular amyloid beta protein (1–42) induces rapid cellular degeneration: evidence for AbetaP channel-mediated cellular toxicity. FASEB J 14:1233–1243
  PubMed CAS Google Scholar
• Lau TL, Ambroggio EE, Tew DJ et al (2006) Amyloid-beta peptide disruption of lipid membranes and the effect of metal ions. J Mol Biol 356:759–770
  PubMed CAS Google Scholar
• Holscher C (1998) Possible causes of Alzheimer’s disease: amyloid fragments, free radicals, and calcium homeostasis. Neurobiol Dis 5:129–141
  PubMed CAS Google Scholar
• Lin H, Bhatia R, Lal R (2001) Amyloid beta protein forms ion channels: implications for Alzheimer’s disease pathophysiology. FASEB J 15:2433–2444
  PubMed CAS Google Scholar
• Kourie JI, Henry CL, Farrelly P (2001) Diversity of amyloid beta protein fragment [1–40]-formed channels. Cell Mol Neurobiol 21:255–284
  PubMed CAS Google Scholar
• Demuro A, Mina E, Kayed R et al (2005) Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J Biol Chem 280:17294–17300
  PubMed CAS Google Scholar
• Kayed R, Head E, Thompson JL et al (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300:486–489
  PubMed CAS Google Scholar
• Kourie JI, Culverson AL, Farrelly PV et al (2002) Heterogeneous amyloid-formed ion channels as a common cytotoxic mechanism: implications for therapeutic strategies against amyloidosis. Cell Biochem Biophys 36:191–207
  PubMed CAS Google Scholar
• Verdier Y, Zarandi M, Penke B (2004) Amyloid beta-peptide interactions with neuronal and glial cell plasma membrane: binding sites and implications for Alzheimer’s disease. J Pept Sci 10:229–248
  PubMed CAS Google Scholar
• Yan SD, Chen X, Fu J et al (1996) RAGE and amyloid-β peptide neurotoxicity in Alzheimer’s disease. Nature 382:685–691
  PubMed CAS Google Scholar
• Arancio O, Zhang HP, Chen X et al (2004) RAGE potentiates Abeta-induced perturbation of neuronal function in transgenic mice. EMBO J 23:4096–4105
  PubMed CAS Google Scholar
• Shibata M, Yamada S, Kumar SR et al (2000) Clearance of Alzheimer’s amyloid-beta(1–40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest 106:1489–1499
  Article PubMed CAS Google Scholar
• Deane R, Wu Z, Sagare A et al (2004) LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron 43:333–344
  PubMed CAS Google Scholar
• De Felice FG, Velasco PT, Lambert MP et al (2007) Abeta oligomers induce neuronal oxidative stress through an N-methyl-d-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J Biol Chem 282:11590–11601
  PubMed Google Scholar
• Sabo S, Lambert MP, Kessey K et al (1995) Interaction of beta-amyloid peptides with integrins in a human nerve cell line. Neurosci Lett 184:25–28
  PubMed CAS Google Scholar
• Bi X, Gall CM, Zhou J et al (2002) Uptake and pathogenic effects of amyloid beta peptide 1–42 are enhanced by integrin antagonists and blocked by NMDA receptor antagonists. Neuroscience 112:827–840
  PubMed CAS Google Scholar
• Coulson EJ (2006) Does the p75 neurotrophin receptor mediate Abeta-induced toxicity in Alzheimer’s disease? J Neurochem 98:654–660
  PubMed CAS Google Scholar
• Zhang Y, Hong Y, Bounhar Y et al (2003) p75 neurotrophin receptor protects primary cultures of human neurons against extracellular amyloid beta peptide cytotoxicity. J Neurosci 23:7385–7394
  PubMed CAS Google Scholar
• Perini G, Della-Bianca V, Politi V et al (2002) Role of p75 neurotrophin receptor in the neurotoxicity by beta-amyloid peptides and synergistic effect of inflammatory cytokines. J Exp Med 195:907–918
  PubMed CAS Google Scholar
• Crouch PJ, Blake R, Duce JA et al (2005) Copper-dependent inhibition of human cytochrome c oxidase by a dimeric conformer of amyloid-beta1–42. J Neurosci 25:672–679
  PubMed CAS Google Scholar
• Devi L, Prabhu BM, Galati DF et al (2006) Accumulation of amyloid precursor protein in the mitochondrial import channels of human Alzheimer’s disease brain is associated with mitochondrial dysfunction. J Neurosci 26:9057–9068
  PubMed CAS Google Scholar
• Manczak M, Anekonda TS, Henson E et al (2006) Mitochondria are a direct site of A beta accumulation in Alzheimer’s disease neurons: implications for free radical generation and oxidative damage in disease progression. Hum Mol Genet 15:1437–1449
  PubMed CAS Google Scholar
• Caspersen C, Wang N, Yao J et al (2005) Mitochondrial Abeta: a potential focal point for neuronal metabolic dysfunction in Alzheimer’s disease. FASEB J 19:2040–2041
  PubMed CAS Google Scholar
• Lustbader JW, Cirilli M, Lin C et al (2004) ABAD directly links Abeta to mitochondrial toxicity in Alzheimer’s disease. Science 304:448–452
  PubMed CAS Google Scholar
• Takuma K, Yao J, Huang J et al (2005) ABAD enhances Abeta-induced cell stress via mitochondrial dysfunction. FASEB J 19:597–598
  PubMed CAS Google Scholar
• White AR, Guirguis R, Brazier MW et al (2001) Sublethal concentrations of prion peptide PrP106-126 or the amyloid beta peptide of Alzheimer’s disease activates expression of proapoptotic markers in primary cortical neurons. Neurobiol Dis 8:299–316
  PubMed CAS Google Scholar
• Ivins KJ, Bui ET, Cotman CW (1998) Beta-amyloid induces local neurite degeneration in cultured hippocampal neurons: evidence for neuritic apoptosis. Neurobiol Dis 5:365–378
  PubMed CAS Google Scholar
• Nakagawa T, Zhu H, Morishima N et al (2000) Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-beta. Nature 403:98–103
  PubMed CAS Google Scholar
• Casas C, Sergeant N, Itier JM et al (2004) Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated Abeta42 accumulation in a novel Alzheimer transgenic model. Am J Pathol 165:1289–1300
  PubMed CAS Google Scholar
• Gomez-Ramos P, Asuncion Moran M (2007) Ultrastructural localization of intraneuronal Abeta-peptide in Alzheimer disease brains. J Alzheimers Dis 11:53–59
  PubMed CAS Google Scholar
• Wegiel J, Kuchna I, Nowicki K et al (2007) Intraneuronal Abeta immunoreactivity is not a predictor of brain amyloidosis-beta or neurofibrillary degeneration. Acta Neuropathol (Berl) 113:389–402
  CAS Google Scholar
• Butterfield DA, Perluigi M, Sultana R (2006) Oxidative stress in Alzheimer’s disease brain: new insights from redox proteomics. Eur J Pharmacol 545:39–50
  PubMed CAS Google Scholar
• Behl C, Davis JB, Lesley R et al (1994) Hydrogen peroxide mediates amyloid beta protein toxicity. Cell 77:817–827
  PubMed CAS Google Scholar
• Cuajungco MP, Goldstein LE, Nunomura A et al (2000) Evidence that the beta-amyloid plaques of Alzheimer’s disease represent the redox-silencing and entombment of Abeta by zinc. J Biol Chem 275:19439–19442
  PubMed CAS Google Scholar
• Huang X, Atwood CS, Hartshorn MA et al (1999) The Aβ peptide of Alzheimer’s disease directly produces hydrogen peroxide through metal reduction. Biochemistry 38:7609–7616
  PubMed CAS Google Scholar
• Huang X, Cuajungco MP, Atwood CS et al (1999) Cu(II) potentiation of alzheimer abeta neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction. J Biol Chem 274:37111–37116
  PubMed CAS Google Scholar
• Barnham KJ, Ciccotosto GD, Tickler AK et al (2003) Neurotoxic, redox-competent Alzheimer’s beta-amyloid is released from lipid membrane by methionine oxidation. J Biol Chem 278:42959–42965
  PubMed CAS Google Scholar
• Ciccotosto GD, Tew D, Curtain CC et al (2004) Enhanced toxicity and cellular binding of a modified amyloid beta peptide with a methionine to valine substitution. J Biol Chem 279:42528–42534
  PubMed CAS Google Scholar
• Ali FE, Separovic F, Barrow CJ et al (2005) Methionine regulates copper/hydrogen peroxide oxidation products of Abeta. J Pept Sci 11:353–360
  PubMed CAS Google Scholar
• Schiewe AJ, Margol L, Soreghan BA et al (2004) Rapid characterization of amyloid-beta side-chain oxidation by tandem mass spectrometry and the scoring algorithm for spectral analysis. Pharm Res 21:1094–1102
  PubMed CAS Google Scholar
• Curtain CC, Ali F, Volitakis I et al (2001) Alzheimer’s disease amyloid-beta binds copper and zinc to generate an allosterically ordered membrane-penetrating structure containing superoxide dismutase-like subunits. J Biol Chem 276:20466–20473
  PubMed CAS Google Scholar
• Butterfield DA, Griffin S, Munch G et al (2002) Amyloid beta-peptide and amyloid pathology are central to the oxidative stress and inflammatory cascades under which Alzheimer’s disease brain exists. J Alzheimers Dis 4:193–201
  PubMed CAS Google Scholar
• Varadarajan S, Kanski J, Aksenova M et al (2001) Different mechanisms of oxidative stress and neurotoxicity for Alzheimer’s A beta(1–42) and A beta(25–35). J Am Chem Soc 123:5625–5631
  PubMed CAS Google Scholar
• Pogocki D, Schoneich C (2002) Redox properties of Met(35) in neurotoxic beta-amyloid peptide. A molecular modeling study. Chem Res Toxicol 15:408–418
  PubMed CAS Google Scholar
• Naslund J, Schierhorn A, Hellman U et al (1994) Relative abundance of Alzheimer Abeta amyloid peptide variants in Alzheimer disease and normal aging. Proc Natl Acad Sci U S A 91:8378–8382
  PubMed CAS Google Scholar
• Kuo YM, Kokjohn TA, Beach TG et al (2001) Comparative analysis of amyloid-beta chemical structure and amyloid plaque morphology of transgenic mouse and Alzheimer’s disease brains. J Biol Chem 276:12991–12998
  PubMed CAS Google Scholar
• Dong J, Atwood CS, Anderson VE et al (2003) Metal binding and oxidation of amyloid-beta within isolated senile plaque cores: Raman microscopic evidence. Biochemistry 42:2768–2773
  PubMed CAS Google Scholar
• Chen K, Kazachkov M, Yu PH (2007) Effect of aldehydes derived from oxidative deamination and oxidative stress on beta-amyloid aggregation; pathological implications to Alzheimer’s disease. J Neural Transm 114:835–839
  PubMed CAS Google Scholar
• Ali FE, Barnham KJ, Barrow CJ et al (2004) Metal catalyzed oxidation of tyrosine residues by different oxidation systems of copper/hydrogen peroxide. J Inorg Biochem 98:173–184
  PubMed CAS Google Scholar
• Metodiewa D (1998) Molecular mechanisms of cellular injury produced by neurotoxic amino acids that generate reactive oxygen species. Amino Acids 14:181–187
  PubMed CAS Google Scholar
• Leeuwenburgh C, Hansen PA, Holloszy JO et al (1999) Hydroxyl radical generation during exercise increases mitochondrial protein oxidation and levels of urinary dityrosine. Free Radic Biol Med 27:186–192
  PubMed CAS Google Scholar
• Lovell MA, Xie C, Markesbery WR (1998) Decreased glutathione transferase activity in brain and ventricular fluid in Alzheimer’s disease. Neurology 51:1562–1566
  PubMed CAS Google Scholar
• Atwood CS, Perry G, Zeng H et al (2004) Copper mediates dityrosine cross-linking of Alzheimer’s amyloid-beta. Biochemistry 43:560–568
  PubMed CAS Google Scholar
• Opazo C, Huang X, Cherny RA et al (2002) Metalloenzyme-like activity of Alzheimer’s disease beta-amyloid. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H2O2. J Biol Chem 277:40302–40308
  PubMed CAS Google Scholar
• Barnham KJ, Haeffner F, Ciccotosto GD et al (2004) Tyrosine gated electron transfer is key to the toxic mechanism of Alzheimer’s disease beta-amyloid. FASEB J 18:1427–1429
  PubMed CAS Google Scholar
• Roher A, Wolfe D, Palutke M et al (1986) Purification, ultrastructure, and chemical analysis of Alzheimer disease amyloid plaque core protein. Proc Natl Acad Sci USA 83:2662–2666
  PubMed CAS Google Scholar
• Moret V, Laras Y, Pietrancosta N et al (2006) 1,1′-Xylyl bis-1,4,8,11-tetraaza cyclotetradecane: a new potential copper chelator agent for neuroprotection in Alzheimer’s disease. Its comparative effects with clioquinol on rat brain copper distribution. Bioorg Med Chem Lett 16:3298–3301
  PubMed CAS Google Scholar
• Lee JY, Friedman JE, Angel I et al (2004) The lipophilic metal chelator DP-109 reduces amyloid pathology in brains of human beta-amyloid precursor protein transgenic mice. Neurobiol Aging 25:1315–1321
  PubMed CAS Google Scholar
• Cherny RA, Atwood CS, Xilinas ME et al (2001) Treatment with a copper–zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer’s disease transgenic mice. Neuron 30:665–676
  PubMed CAS Google Scholar
• Perluigi M, Joshi G, Sultana R et al (2006) In vivo protection by the xanthate tricyclodecan-9-yl-xanthogenate against amyloid beta-peptide (1–42)-induced oxidative stress. Neuroscience 138:1161–1170
  PubMed CAS Google Scholar
• Ritchie CW, Bush AI, Mackinnon A et al (2003) Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol 60:1685–1691
  PubMed Google Scholar
• White AR, Du T, Laughton KM et al (2006) Degradation of the Alzheimer disease amyloid beta-peptide by metal-dependent up-regulation of metalloprotease activity. J Biol Chem 281:17670–17680
  PubMed CAS Google Scholar
• Crouch PJ, Barnham KJ, Bush AI et al (2006) Therapeutic treatments for Alzheimer’s disease based on metal bioavailability. Drug News Perspect 19:469–474
  PubMed CAS Google Scholar